跳转至内容
Merck
CN

SML2838

AP20187

≥98% (HPLC), powder, protein dimerization inducer

别名:

(2S,2′S)-1-[(2S)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl]-2-piperidinecarboxylic acid, 2,2′-[[2-[(dimethylamino)methyl]-1,3-propanediyl]bis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene[(1R)-3-(3,4-dimethoxyphenyl)propylidene]]] ester

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C82H107N5O20
化学文摘社编号:
195514-80-8
分子量:
1482.75
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD28167729

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

AP20187, ≥98% (HPLC)

SMILES string

N2([C@@H](CCCC2)C(=O)O[C@H](CCc8cc(c(cc8)OC)OC)c3cc(ccc3)OCC(=O)NCC(CN(C)C)CNC(=O)COc4cc(ccc4)[C@H](OC(=O)[C@H]6N(CCCC6)C(=O)[C@@H](CC)c7cc(c(c(c7)OC)OC)OC)CCc5cc(c(cc5)OC)OC)C(=O)[C@@H](CC)c1cc(c(c(c1)OC)OC)OC

InChI

1S/C82H107N5O20/c1-15-61(57-43-71(98-9)77(102-13)72(44-57)99-10)79(90)86-37-19-17-27-63(86)81(92)106-65(33-29-52-31-35-67(94-5)69(39-52)96-7)55-23-21-25-59(41-55)104-50-75(88)83-47-54(49-85(3)4)48-84-76(89)51-105-60-26-22-24-56(42-60)66(34-30-53-32-36-68(95-6)70(40-53)97-8)107-82(93)64-28-18-20-38-87(64)80(91)62(16-2)58-45-73(100-11)78(103-14)74(46-58)101-12/h21-26,31-32,35-36,39-46,54,61-66H,15-20,27-30,33-34,37-38,47-51H2,1-14H3,(H,83,88)(H,84,89)/t61-,62-,63-,64-,65+,66+/m0/s1

InChI key

NSBGUMKAXUXKGI-BPNHAYRBSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

100

相关类别

Biochem/physiol Actions

AP20187 is a synthetic and cell-permeable FK506 (tacrolimus) analog that acts as a chemical dimerizer, a chemical inducer of dimerization (CID), to reversibly dimerize and activate fusion proteins containing a growth factor receptor signaling DmrB domain. It has been used to induce oligomerization of cell surface receptor proteins and to study the activity and/or re-localization of any protein that affected by oligomerization. AP20187 has been found to act as a senolytic. In a transgenic mouse model that expresses the FK506-binding protein–caspase 8 (FKBP–Casp8) fusion protein, AP20187 activated FKBP-fused Casp8 in senescent cells resulting in apoptosis of the cells resulting in delayed tumorigenesis , diminished age-related organ deterioration, and extended life span.
Synthetic and cell-permeable FK506 (tacrolimus) analog that acts as a dimerizer and activator of fusion proteins; senolytic

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000466349
0000466350
0000466350
0000466349
0000401400

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Aurelie Bedel et al.
Stem cells translational medicine, 6(2), 382-393 (2017-02-14)
Iatrogenic tumorigenesis is a major limitation for the use of human induced pluripotent stem cells (hiPSCs) in hematology. The teratoma risk comes from the persistence of hiPSCs in differentiated cell populations. Our goal was to evaluate the best system to
David W Chang et al.
The Journal of biological chemistry, 278(19), 16466-16469 (2003-03-15)
Proteolytic activation of initiator procaspases is a crucial step in the cellular commitment to apoptosis. Alternative models have been postulated for the activation mechanism, namely the oligomerization or induced proximity model and the allosteric regulation model. While the former holds
Darren J Baker et al.
Nature, 530(7589), 184-189 (2016-02-04)
Cellular senescence, a stress-induced irreversible growth arrest often characterized by expression of p16(Ink4a) (encoded by the Ink4a/Arf locus, also known as Cdkn2a) and a distinctive secretory phenotype, prevents the proliferation of preneoplastic cells and has beneficial roles in tissue remodelling

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持